Stage IV HER2-Positive Non-Small Cell Lung Cancer: Samantha's Patient Story

Patient Info: Samantha, Female | Stage IV

Biomarkers: HER2 mutation

Metastatic Site: Lungs/pleural fluid; liver

As of November 2024, Samantha reported a 55% reduction across the board on chemotherapy plus immunotherapy, few side effects, improved energy, and enough function to hike, work, and feel more like herself.

The Patient StoryRead more →

Stage 1 lung cancer found after chest injury

Patient Info: Anonymized, Female, 70+

No lung cancer recurrence and no cardiovascular events were reported 12 months after right lower lobectomy and lymph node dissection for Stage IA2 papillary lung adenocarcinoma.

PubMed CentralRead more →

Stage 4 small-cell lung cancer: ongoing response to immunotherapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1-negative

Metastatic Site: liver, bone, brain

Extensive-stage small-cell lung cancer had complete response in the primary lung, liver, bone, and treated brain lesions, with partial response in hilar/mediastinal nodes; after about 20 months of serplulimab-based first-line therapy, the patient had no deterioration, no immunotherapy-related adverse effects, and high quality of life.

PubMed CentralRead more →

Stage IV Lung Cancer: Ashley's Patient Story

Patient Info: Ashley Smith, Female, Under 40 | Stage IV

Metastatic Site: pleura / malignant pleural fluid

As of November 2024, Ashley was living with Stage IV lung cancer and staying active, but the available source text did not state her treatment regimen or response status.

The Patient StoryRead more →

Stage III MET Exon 14-Positive Lung Adenocarcinoma Treated With Targeted Therapy Before Surgery

Patient Info: Anonymized, male, 60s | Stage I

Biomarkers: MET exon 14 skipping mutation; TP53 mutation

Postoperative pathology showed no involved lymph nodes and a lower pathologic Stage I group after treatment. No relapse was seen at the 6-month postoperative follow-up.

PubMed CentralRead more →

Stage 3C lung cancer: complete remission on immunotherapy and chemotherapy

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: EGFR wild-type; ALK rearrangement not detected; PD-L1 <1%

Complete tumor remission with no recurrence more than 6 months after durvalumab, tremelimumab, carboplatin, and nab-paclitaxel for Stage IIIC driver-negative NSCLC, despite severe immune, infectious, cardiac, renal, and fistula complications that later resolved or stabilized.

PubMed CentralRead more →

Recurrent Lung Adenocarcinoma Complicated by a Tracheopericardial Fistula

Patient Info: Anonymized, male, 70+ | Stage II

Biomarkers: No gene mutations identified on postoperative testing

He died during the June 2024 admission, about 7½ years after his November 2016 lung-cancer diagnosis, after massive hemoptysis occurred in the setting of a tracheopericardial fistula and recurrent cancer.

PubMed CentralRead more →

Stage IV Non-Small Cell Lung Cancer: Ashley's Survivor Story

Patient Info: Ashley Vasallo, Female, Under 40 | Stage IV

Biomarkers: No actionable driver biomarker identified; rare fusion reported

Metastatic Site: spine, hip/bone, chest cavity

As of October 2024, Ashley reported clear labs and scans after radiation for small chest-cavity and hip lesions, with scans planned every 3 months.

The Patient StoryRead more →

Lung Adenocarcinoma Removed During Combined Surgery for a Thymoma

Patient Info: Anonymized, female, 40s

No signs of lung-cancer recurrence were seen during nearly 2 years of follow-up after surgery.

PubMed CentralRead more →

Stage III Lung Adenocarcinoma Treated With Complex Lung-Sparing Surgery and Adjuvant Therapy

Patient Info: Anonymized, male, Under 40 | Stage III

Biomarkers: PD-L1 high expression

Follow-up through 3 years after surgery showed no recurrence or metastasis, with stable lung function and unrestricted physical activity.

PubMed CentralRead more →

Two Severe Kidney Injuries After Lung Cancer Immunotherapy

Patient Info: Anonymized, Male, 70+

The lung cancer remained stable without further anticancer treatment, while the patient remained dependent on hemodialysis after the second kidney injury and continued tapering prednisolone.

PubMed CentralRead more →

Stage I Lung Adenocarcinoma With Later Kidney Metastases Responding to Osimertinib

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; RB1 mutation; MAP3K1 mutation; PD-L1 negative

Metastatic Site: kidneys, peritoneal lymph nodes

Osimertinib produced a partial response within 6 weeks after metastatic recurrence in the kidneys. She remained alive and continued targeted treatment.

PubMed CentralRead more →

Stage IV EGFR-Mutant Lung Adenocarcinoma With Severe Respiratory Failure Responding to Almonertinib

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion

Within days of starting almonertinib, lung abnormalities improved enough for extubation. A March 2024 PET-CT showed satisfactory disease control with a partial response, and outpatient follow-up was ongoing with good performance status.

PubMed CentralRead more →

Metastatic Lung Cancer With Morphine-Induced Fever During Palliative Radiation

Patient Info: Anonymized, female, 50s | Stage IV

Metastatic Site: brain, bone

She remained on dacomitinib while receiving radiation for painful metastatic disease in 2022. After morphine was identified as the cause of recurrent fever and stopped, her symptoms resolved and she was discharged in satisfactory condition.

PubMed CentralRead more →

Lung Cancer: Pascal's Survivor Story

Patient Info: Pascal, Male, 60s

As of the September 2024 article update, Pascal had resumed sports, felt well, and had been in complete remission for 26 months after an immunotherapy clinical trial following chemotherapy and radiation failure.

Stage IV Lung Cancer: Florence's Patient Story

Patient Info: Florence, Female, 40s | Stage IV

Metastatic Site: Brain

As of the September 2024 article update, Florence was living with metastatic lung cancer, traveling every 3 weeks for immunotherapy in a clinical trial, and reported less fatigue, more energy, and a return to sports and social life.

Stage 1 lung adenocarcinoma: no recurrence after 2 years

Patient Info: Anonymized, Female, 50s | Stage I

No recurrence or surgical complications 2 years after uniportal video-assisted thoracoscopic left middle lobectomy and left upper-lobe wedge resection for Stage IB lung adenocarcinoma in situs inversus totalis.

PubMed CentralRead more →

Stage 4 lung cancer: stable disease on immunotherapy combination

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: TP53, and MSH2 mutations; PD-L1 locally positive; Ki-67 20%; ALK negative. Markers otherwise supported lung cancer.

Metastatic Site: left atrium, right adrenal gland, skull; hilar and…

Stage IVB NSCLC remained clinically stable during carboplatin, pemetrexed, and tislelizumab, but treatment was stopped because of financial and psychological burden; later cancer status was not reported.

PubMed CentralRead more →

Stage 4 lung LCNEC: major response to chemotherapy plus immunotherapy

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: Large-cell neuroendocrine lung cancer markers were positive. PD-L1 was negative

Metastatic Site: left adrenal gland

By July 2024, PET-CT showed complete metabolic response of the adrenal metastasis, no visible adrenal disease, no pulmonary recurrence, and no distant metastasis after immunochemotherapy, lobectomy, adjuvant therapy, and serplulimab maintenance.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Lindsay's Patient Story

Patient Info: Lindsay Wagner, Female, 40s | Stage IV

Biomarkers: ALK-positive mutation / ALK rearrangement

Metastatic Site: brain; liver; bone; kidneys; lungs;…

As of September 2024, Lindsay was still on lorlatinib/Lorbrena with her lungs, liver, and kidneys described as stable, while isolated brain/bone areas were treated with radiation and monitored.

The Patient StoryRead more →

Stage IA1 adenosquamous lung cancer found after traumatic hemoptysis and lobectomy

Patient Info: Anonymized, Male, 60s

As of September 2024, he had no recurrence 2 years after video-assisted thoracoscopic right upper lobectomy for incidentally discovered Stage IA1 adenosquamous lung carcinoma.

PubMed CentralRead more →

ALK-positive lung cancer spreading to both breasts after years of targeted therapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: ALK-positive, ALK mutation

Metastatic Site: bilateral breasts

At age 51, about 10 years after his Stage IV diagnosis, he remained alive with stable disease 8 months after removal of bilateral breast metastases while continuing maintenance therapy.

PubMed CentralRead more →

Pulmonary large cell neuroendocrine cancer treated with airway procedures and pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR negative, ALK negative, ROS1 negative, TP53 negative, PD-L1 <1%, TMB 28.3 mut/Mb

Metastatic Site: bilateral lungs

Pembrolizumab-based treatment produced a complete remission, but multiple intrapulmonary metastases recurred in October 2021 after an 18-month progression-free interval. Further local airway treatment was performed and pembrolizumab continued.

PubMed CentralRead more →

Stage 4 small-cell lung cancer: complete response on durvalumab

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: pericardial effusion; left supraclavicular lymph node

As of July 2024, she had clinical complete response after chemoimmunotherapy and chest radiation, improving immune-related bone changes, and ongoing durvalumab maintenance every 4 weeks.

PubMed CentralRead more →